Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed ...

Semaglutide use in patients with type 2 diabetes moderately increases the risk of nonarteritic anterior ischemic optic neuropathy.

The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.

The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...

Semaglutide is a glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar levels. Because of outsized demand for ...

Semaglutide injections, which have become a popular treatment option for weight loss as well as Type 2 diabetes, have been considered to be in a shortage since 2022. This could affect Hims & Hers, ...

Discover how this diabetes drug is revolutionizing heart health. Learn about its surprising benefits in reducing cardiovascular risks and mortality.

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the ...

Shares of Hims & Hers Health ( HIMS -24.30%) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost ...

The FDA has determined that the nationwide shortage of semaglutide injection, used for both diabetes and weight loss, is resolved after more than two years of limited availability due to high demand.

Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...

“We are pleased the FDA has declared that supply of the only real, FDA-approved semaglutide medicines is resolved, affirming ...